Thus, given their ability to regulate both β1 and β3 integrin function, dysregulation of galectin-1 and galectin-3 expression in the tumor microenvironment may have a profound impact on the efficacy of therapies targeting RTKs. This evidence concerns the gene LGALS3 and neoplasm.